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African Americans have the highest incidence of end-stage
renal disease (ESRD) in the United States. To understand the
basis of this disparity, we examined data from a prepaid,
integrated health system for this retrospective cohort study
of members who had one or more serum creatinine tests
performed over a 9-year period. The cohort included 182,959
adults (8% black) with stage 3 or 4 chronic kidney disease
based on their estimated glomerular filtration rate (eGFR).
Competing-risk methods were used to determine the
incidence of ESRD and death prior to ESRD. At all follow-up
times and from any entry eGFR, the cumulative incidence of
ESRD was significantly greater in blacks. The age and gender-
adjusted hazard ratios for ESRD and death prior to ESRD in
blacks compared to non-blacks were 1.83 and 1.15,
respectively. Increased survival free of ESRD was found in
blacks 70 years and older with eGFR stage 4. The hazard ratio
for the combined outcomes of ESRD or death was 1.31 in
blacks as compared to non-blacks. Despite equivalent health
insurance benefits, blacks with chronic kidney disease were
at increased risk for ESRD and death prior to ESRD. Compared
to non-blacks, blacks with chronic kidney disease were twice
as likely to enter into ESRD as to die prior to ESRD.
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End-stage renal disease (ESRD) is a growing public health
problem that disproportionately affects African Americans.1
Although the causes of the disparity remain unclear, the
magnitude of the problem is well known. In 2004, the age-
and sex-adjusted incidence of ESRD in Blacks was 2.6 times
higher than that in non-Blacks.1 Therapy for ESRD with
dialysis or kidney transplantation is life-saving, but mortality
after the onset of ESRD remains high: for those starting
dialysis in 2001, the 3-year survival probability was just 54%.1
Although ESRD is a feared result of chronic kidney disease
(CKD), death before ESRD is more common.2–6 Unfortu-
nately, the number of patients with CKD is large (recently
estimated at 13% of the US population) and is increasing.1,7
The racial disparity in ESRD incidence may be due to
several population differences, including the risks that lead to
kidney disease, kidney disease type and severity, and
comorbidities that affect mortality before ESRD. These
population differences may result from more distal causes
such as variations in genetic expression, environmental
exposures, health-related behavior, health-care access and
quality, or response to therapy.8–11 Regardless of the ultimate
causes, the basic epidemiological forces driving the increase
in ESRD incidence for Blacks are only partly understood.
Driving forces may include increased onset of CKD,10
increased rate of kidney function loss,12,13 and a survival
advantage in late-stage CKD.14–16 Better understanding of
these forces will help target research and interventions
designed to reduce disparities in CKD. For example, if
kidney function loss is greater in Blacks, then efforts might be
focused on disease initiation or the point at which kidney
function diverges and the disparity begins. Alternatively, if
there is a survival advantage for Blacks in late-stage CKD,
then either early-stage CKD-related mortality in Blacks
(resulting in a healthy survivor effect) or late-stage CKD
mortality in non-Blacks might be targeted.
In this study, we examined disparities in ESRD and death
before ESRD as a first step toward identifying the forces
driving racial disparities in ESRD. Estimates of the simulta-
neous incidence of ESRD and death before ESRD that
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account for competing risks are needed to understand the
extent of racial disparities in these two linked events. Study
subjects were members of a prepaid, integrated health system.
This setting is particularly relevant because if racial
disparities are substantially smaller under conditions of
equivalent health insurance benefits, then access to care may
be implicated as a focus area for research and policy.
RESULTS
Of the 2,515,552 potential subjects with estimable kidney
function before an end point or censoring, 182,959 had a
randomly selected study entry estimated glomerular filtration
rate (eGFR) from 15 to o60 ml/min per 1.73 m2 (the study
cohort, see Figure 1). The study cohort is compared with the
source population (that is, all adult health plan members) in
Table 1. Subjects in the study cohort were significantly
(Po0.001) older and more often female than in the source
population. The racial distribution of the source population
and the study cohort is shown in Table 1. In the source
population, Blacks were 1.4 times more likely to have had a
serum creatinine test (Po0.001). Information about race was
more complete in persons with one or more serum creatinine
tests and at lower eGFR levels. The median household
income, based on US Census Block Group, of the study
cohort was significantly less in Blacks than that in non-Blacks
(median $47,500 vs $59,369 per year, Po0.001).
Subject characteristics by eGFR strata and race are
provided in Table 2. The distribution of Black and non-
Black race was significantly different (Po0.001) across eGFR
strata, with relatively more Blacks at lower eGFR. The median
number of serum creatinine tests was greater in Blacks (21 vs
11, Po0.001). The mean observation time from the entry
eGFR to an end point or censoring was 1.69 years in Blacks
and 1.64 years in non-Blacks (Po0.001). Before the end of
the study period, 11.0% of Blacks and 17.7% of non-Blacks
had disenrolled from the health plan before experiencing
ESRD.
In the total cohort, death was more common than ESRD,
especially in non-Blacks (Table 2). The crude rate of death
before ESRD (per 1000 person-years) was 99 (95%
confidence interval (CI) 96–102) in Blacks and 87 (95% CI
86–88) in non-Blacks; the crude rate of ESRD (per 1000
person-years) was 37 (95% CI 35–39) in Blacks and 12 (95%
CI 11–13) in non-Blacks. Thus, the overall ratio of death/
ESRD was 2.7 in Blacks and 7.3 in non-Blacks. Death and
ESRD occurred at a younger age in Blacks. The mean age at
death was 74.9 years (s.d. 12.0) in Blacks and 79.0 years (s.d.
10.9) in non-Blacks (Po0.001). The mean age at the
beginning of ESRD treatment was 62.4 years (s.d. 13.7) in
Blacks and 63.9 years (s.d. 13.9) in non-Blacks (Po0.001).
The Black and non-Black populations had different
patterns in the relative incidence of ESRD and death before
ESRD. The cumulative incidence curves in Figure 2 show the
5,004,022 adult health
plan members during 
1/1/1998-31/12/2006  
2,542,842 members with
≥1 serum creatinine tests
during the study period
2,515,552 members with
one or more eGFR ≥15
during the observation time 
182,959 subjects with
randomly selected eGFR 
≥15 to <60 (study cohort) 
Excluded:
1. No exact date of death (1286) 
2. No serum creatinine test before first
    disenrollment (11,956)  
3. ESRD (3978) or all eGFR <15 (1417) 
4. Missing race after imputation (8653) 
Figure 1 | Flow diagram of study cohort assembly.
Table 1 | Demographic characteristics of adult health plan members (the source population), the subpopulation with one or
more serum creatinine tests, and those with an eGFR of 15 to o60ml/min per 1.73m2 (the study cohort)
Characteristic
Source population:
adult members
(n=5,004,022)a
Subpopulation:
X1 serum creatinine tests
(n=2,542,842)
Study cohort:
eGFR 15 to o60b
(n=182,959)
Age (years): median (25th to 75th percentile) 33.5, 22.3–46.7 41.3, 29.3–53.8 69.4, 60.3–78.4
Female: n (%) 2,525,769 (50.5) 1,399,183 (55.0) 104,906 (57.3)
Race: Black and non-Black after imputation
Black: n (%) 290,963 (5.8) 202,823 (8.0) 15,484 (8.5)
Non-Black: n (%) 4,419,377 (88.3) 2,230,457 (87.7) 167,475 (91.5)
Not assigned: n (%) 293,682 (5.9) 109,562 (4.3) —
Race: all categories as recorded in health plan files
Black: n (%) 259,494 (5.2) 188,764 (7.4) 15,003 (8.2)
White: n (%) 1,354,233 (27.1) 993,879 (39.1) 112,525 (61.5)
Asian: n (%) 175,330 (3.5) 125,545 (4.9) 8953 (4.9)
Native American: n (%) 3525 (0.1) 2333 (0.1) 142 (0.08)
Other: n (%) 53,089 (1.1) 41,043 (1.6) 2909 (1.6)
Multiple: n (%) 5151 (0.1) 3114 (0.1) 114 (0.06)
Unknown: n (%) 3,153,200 (63.0) 1,188,164 (46.7) 43,313 (23.7)
aGreater than 17 years old from 1998 to 2006.
bUnit: ml/min per 1.73m2.
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occurrence of ESRD and death before ESRD to 8 years of
follow-up. Within every eGFR strata, Blacks had a greater
cumulative incidence of ESRD than non-Blacks (Po0.001);
the difference appeared early and showed little or no decrease
in magnitude toward the end of the follow-up period. The
cumulative incidence of death before ESRD was significantly
greater (Po0.001) in Blacks than that in non-Blacks at an
eGFR of 45–60 ml/min per 1.73 m2. For patients with an entry
eGFR of 30–44 ml/min per 1.73 m2 and lower, Blacks had a
significantly (Po0.001) lesser cumulative incidence of death,
and the difference appeared to widen during follow-up. After
about 3 years of follow-up in Blacks and 6 years in non-
Blacks, the cumulative incidence of death was actually lower
at an eGFR of 15–29 ml/min per 1.73 m2 than it was at an
eGFR of 30–44 ml/min per 1.73 m2. The combined events of
ESRD and death before ESRD were significantly more
common in Blacks than in non-Blacks, but the difference
was not large at an eGFR of 30–44 ml/min per 1.73 m2 and
below. At no time were the combined events more common
in non-Blacks.
Table 3 shows the relative occurrence of death/ESRD using
ratios of the cumulative incidence. In the raw (unadjusted)
data, death before ESRD was much more likely than ESRD.
The risk of ESRD increased at lower eGFR and with longer
survival. By 2 years after an entry eGFR of 15–29 ml/min
per 1.73 m2, Blacks were more likely to enter ESRD than
die. These death/ESRD ratios were adjusted for age and
sex differences to aid comparison between Blacks and non-
Blacks (Table 3). The ratio in Blacks was compared with that
in non-Blacks. Overall, Blacks were about twice as likely to
enter ESRD as die before ESRD; conversely, non-Blacks were
about twice as likely to die rather than enter ESRD. For
example, 5 years after entry an eGFR of 15–29, 30–44, and
45–60 ml/min per 1.73 m2, Blacks were 1.49, 2.27, and 2.54
times more likely than non-Blacks to enter ESRD rather
than die first.
The Fine and Gray27 regression method was used to
estimate the risk of ESRD and death before ESRD in Blacks vs
non-Blacks adjusted for age, sex, and eGFR (Table 4). The
hazard ratio (HR) for Blacks vs non-Blacks was 1.83 (95% CI
Table 2 | Subject characteristics by eGFR strata and race
Entry eGFR 15 to o30a
(n=15,334)
Entry eGFR 30 to o45
(n=40,646)
Entry eGFR 45 to o60
(n=126,979)
Total cohort:
entry eGFR 15 to o60
(n=182,959)
Characteristic Black Non-Black Black Non-Black Black Non-Black Black Non-Black
Number (%
of eGFR strata)
2188 (14.3) 13,146 (85.7) 4055 (10.0) 36,591 (90.0) 9241 (7.3) 117,738 (92.7) 15,484 (8.46) 167,475 (91.54)
Age (years):
median (25th
to 75th percentile)
66.9 (56.3–75.9) 72.4 (61.1–80.7) 70.0 (60.8–78.3) 74.5 (64.0–82.1) 67.1 (57.6–75.7) 67.9 (59.4–76.7) 67.9 (58.0–76.4) 69.5 (60.5–78.5)
Female:
number (%
of eGFR strata)
1194 (54.6) 7064 (53.7) 2356 (58.1) 20,592 (56.3) 5465 (59.1) 68,235 (58.0) 9015 (56.2) 95,891 (57.3)
Serum
creatinine tests:
median (25th
to 75th
percentile)
18 (9–31) 16 (8–29) 16 (8–27) 12 (6–21) 11 (6–19) 7 (3–13) 21 (10–40) 11 (4–24)
Entry eGFR:
mean (s.d.)
22.7 (4.5) 23.4 (4.4) 38.6 (4.3) 38.7 (4.2) 53.5 (4.3) 54.0 (4.2) 45.2 (11.9) 48.3 (10.5)
Observation timeb
(days): median
(25th to 75th
percentile)
404 384 608 530 698 645 619 594
(161–850) (139–844) (224–1250) (195–1131) (269–1428) (251–1364) (235–1300) (227–1266)
Censored %
Total 34.19 41.91 62.52 67.11 78.25 84.23 67.90 77.17
Due to end of study 27.01 32.03 52.45 52.44 65.91 64.74 56.89 59.49
Due to disenrollment 7.18 9.88 10.06 14.67 12.34 19.49 11.01 17.68
Death before
ESRD: n/1000
person-years
(95% CI)
167 (154–181) 223 (217–229) 129 (122–136) 143 (140–146) 77 (74–81) 62 (61–63) 99 (96–102) 87 (86–88)
ESRD: n/1000
person-years
(95% CI)
230 (215–246) 138 (133–143) 37 (33–41) 14 (13–15) 7 (6–8) 1.8 (1.7–2.0) 37 (35–39) 12 (11–13)
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.
Differences between Blacks and non-Blacks were significant at Po0.001 across all eGFR strata and the total cohort for age, serum creatinine tests (median test); the total
proportion censored (two-sample proportion test); and the rates of ESRD and death before ESRD (Poisson model). For entry eGFR, differences were significant for an eGFR of
30 to o45ml/min per 1.73m2 at P=0.033 (t-test), and were significant at Po0.001 for all other eGFR strata and the overall study cohort. Differences were non-significant
(P40.05) for an eGFR of 15–29ml/min per 1.73m2 but were significant at Po0.001 across all other eGFR strata and the total cohort for gender, disenrollment (w2 test), and
observation time (median test).
aUnit: ml/min per 1.73m2.
bTime from entry eGFR to the first end point or censoring.
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1.71–1.96) for ESRD, 1.15 (95% CI 1.11–1.19) for death
before ESRD, and 1.31 (95% CI 1.27–1.35) for the combined
outcome of ESRD and death. These results were compared
with those obtained using the subset of subjects whose race
was known from health plan files (see Table 1). In these
subjects, the overall HR was 1.65 (95% CI 1.55–1.77) for
ESRD, 1.07 (95% CI 1.03–1.11) for death before ESRD, and
1.20 (95% CI 1.17–1.24) for the combined outcome. Thus,
the differences between Blacks and non-Blacks are smaller
but still significant in the subset of subjects with known race.
When the regression included interaction terms (Table 4),
significant interactions (all Po0.01) were found between
eGFR and other covariates, and between race and age
(P¼ 0.038 for ESRD, Po0.001 for death before ESRD).
Figure 3 graphs the HR for ESRD and death before ESRD in
Blacks vs non-Blacks by age and entry eGFR. The HR for
death before ESRD in Blacks vs non-Blacks decreased with
increasing age such that the differences in the elderly were
much smaller, whereas the opposite trend was observed for
ESRD. Only at severely decreased eGFR and older ages (for
example, o30 ml/min per 1.73m2 for age 70 years) was the
risk of death lower among Blacks.
DISCUSSION
These data clarify the increased risk of ESRD among African
Americans in two important ways. First, despite equivalent
health insurance benefits, Blacks had a substantially greater
risk of ESRD, regardless of initial kidney function. Second,
the risk of death before ESRD was greater in Blacks, with the
exception of the elderly with severely decreased kidney
function. Together, these risks resulted in an important
finding of our study: Blacks with moderately to severely
decreased kidney function were about twice as likely as non-
Blacks to enter ESRD rather than die first. Blacks with
severely decreased kidney function were more likely to enter
ESRD if they survived for 2 years, in contrast to non-Blacks
and reports in the general population, where even at low
levels of eGFR rates of death exceeded ESRD.2,3
These data provide clues toward understanding of the
major epidemiological forces driving racial disparities in
ESRD incidence and help set the stage for future work. First,
in the raw population data, survival free of ESRD was actually
greater over time in subjects with severely decreased kidney
function than those in the next higher strata (Figure 2). This
effect was more pronounced in the Black population. In
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Figure 2 |Cumulative incidence of ESRD and death before ESRD in Blacks and non-Blacks from a study entry eGFR of 15 too29, 30
to o45, and 45 to o60ml/min per 1.73m2 (raw data). Starting population sizes are given in Table 2. P-values for differences are
indicated for each pair of curves (K-sample test for ESRD and death before ESRD; log-rank test for the combined outcome). Solid lines:
Blacks. Dashed lines: non-Blacks. eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.
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addition, subjects with severely decreased kidney function
were younger than those in the next higher strata (Table 2).
Again, this effect was relatively greater in the Black
population. Taken together, these data suggest a relatively
larger sub-population of younger Blacks with rapidly
deteriorating kidney function. Second, the reversal in risk
of death before ESRD in Blacks vs non-Blacks at older ages
and lower kidney function (see Figure 3) suggests a healthy
survivor effect. This possibility must be tempered by the
recognition of a simultaneously increasing, competing risk of
ESRD.
Given lower rates of death among Blacks in the US dialysis
population, the lower incidence of death before ESRD in
Blacks at very low levels of kidney function is not
unexpected.1 Earlier studies have commented upon a possible
survival advantage among Blacks with CKD.15–17 Compar-
isons with our study are limited as other studies examined
death at any time and such results may be affected by survival
on renal replacement therapy. A recent examination of
NHANES III data reported no effect of the interaction
between race and CKD stage on mortality, yet found higher
risk at lower age, consistent with our results.15 This suggests
the possibility of early death among Blacks with CKD and a
resultant healthy survivor effect in late-stage CKD. The
possibility of a true survival advantage among Blacks at a very
low eGFR is suggested by survival in patients with heart
failure14 and after acute myocardial infarction.16 In the latter
study, a mortality pattern similar to that seen in this study
was observed in Blacks relative to Whites as eGFR declined
under 30 ml/min per 1.734 m2.16 However, conflicting
evidence was found in a pooled analysis of community-
based studies,17 which found an increased risk of all-cause
mortality over 10 years and larger disparities in Blacks
compared with that in Whites at lower eGFR. Given higher
rates of all-cause death among Blacks in the US general
population,18 deaths unrelated to kidney disease may create
the appearance of a healthy survivor effect by confounding
the association between race, kidney function, and death.
More evidence is needed to understand if there exists a racial
disparity in survival during early-stage CKD.
Direct evidence of an increased rate of kidney function
loss among Blacks exists. A large community-based cohort
Table 3 | Ratio of the cumulative incidence of death before
ESRD to the cumulative incidence of ESRD by entry eGFR
strata, race group, and year: adjusted data (bold) and raw
data (italics)
Years from entry eGFR
1 2 3 4 5
45 to o60ml/min per 1.73m2
Black 9.78 5.95 3.61 2.58 2.52
35.67 21.83 13.46 10.18 9.41
Non-Black 19.57 13.55 9.93 7.41 6.39
74.60 55.59 38.45 32.17 29.05
30 to o45ml/min per 1.73m2
Black 1.51 1.02 0.815 0.625 0.564
10.82 5.30 3.80 3.16 2.86
Non-Black 4.35 2.10 1.77 1.52 1.28
23.10 13.39 11.20 9.62 8.83
15 to o29ml/min per 1.73m2
Black 0.432 0.309 0.256 0.242 0.239
1.19 0.80 0.71 0.67 0.65
Non-Black 0.625 0.423 0.363 0.354 0.356
2.32 1.67 1.51 1.45 1.46
eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.
The adjusted data (bold) are directly standardized to the year 2000 US population to
adjust for age and sex differences between the populations represented in each
table cell.
Table 4 | Regression model HR estimates for race (Black vs non-Black) and other covariates regressed on ESRD and death
before ESRD, with and without interactions
HR Estimate s.e. P-value HR Estimate s.e. P-value
ESRD
Black 1.83 0.6033 0.0346 o0.001 0.67 0.4055 0.1607 0.012
eGFR 0.88 0.1299 0.0012 o0.001 0.89 0.1162 0.0046 o0.001
Age 0.96 0.0378 0.0009 o0.001 0.97 0.0278 0.0023 o0.001
Male 1.70 0.5318 0.0276 o0.001 1.40 0.3365 0.0748 o0.001
Black eGFR — — — — 1.03 0.0271 0.0028 o0.001
Age eGFR — — — — 1.00 0.0004 0.0001 o0.001
Male eGFR — — — — 1.01 0.0068 0.0024 0.005
BlackAge — — — — 1.00 0.0043 0.0021 0.038
Death before ESRD
Black 1.15 0.1386 0.0183 o0.001 1.60 0.4722 0.1326 o0.001
eGFR 0.97 0.0265 0.0005 o0.001 0.93 0.0732 0.0032 o0.001
Age 1.07 0.0671 0.0005 o0.001 1.05 0.0444 0.0019 o0.001
Male 1.38 0.3217 0.0103 o0.001 0.98 0.0182 0.0408 0.657
Black eGFR — — — — 1.02 0.0167 0.0014 o0.001
Age eGFR — — — — 1.00 0.0005 0.00004 o0.001
Male eGFR — — — — 1.01 0.0077 0.0009 o0.001
BlackAge — — — — 0.99 0.0141 0.0016 o0.001
eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; HR, hazard ratio.
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study of subjects with hypertension in the Hypertension
Detection and Follow-up Program12 and hypertensive males
from the Multiple Risk Factor Intervention Trail showed a
more rapid kidney function loss in Blacks vs Whites with
similar blood pressure.13 Racial differences in CKD pre-
valence in the United States seem consistent with a rapid loss
of kidney function among Blacks with kidney disease. The
point prevalence of one disease stage relative to others will be
greater for those stages with the longest duration. If kidney
function is dropping rapidly, prevalence may be greater in
stages that last longer, such as normal GFR before CKD or
very low GFR before the start of ESRD therapy. This may
explain, at least in part, why the prevalence of an eGFR of
30–89 ml/min per 1.73 m2 is lower among non-Hispanic
Blacks than that among non-Hispanic Whites (20.5 vs 40.0,
respectively) in the United States.19 The Chronic Renal
Insufficiency Cohort Study will shed more light on progres-
sion to ESRD and death among persons with CKD of defined
cause and of different race/ethnicity.20
A potential shortcoming of this study is that the source
population was not systematically screened for CKD. On the
basis of a comparison of eGFR prevalence in the health plan
to US estimates, it appears that serum creatinine tests
performed for clinical reasons eventually detect most persons
with decreased kidney function. Among US adults aged
19 years and older from 1998 to 1999, the prevalence of an
eGFR of 30–59 and 15–29 ml/min per 1.73 m2 based on a
serum creatinine test was 4.3 and 0.2%, respectively.19
Among health plan members aged 19 years and older who
were continuously enrolled from 1998 to 1999, the prevalence
of an eGFR of 30–59 and 15–29 ml/min per 1.73 m2 was 4.24
and 0.25%, respectively, under the assumption that eGFR was
460 ml/min per 1.73 m2 if no serum creatinine test was
available. Another potential shortcoming is the differences in
ESRD incidence introduced by disparities in dialysis initia-
tion. To assess if a portion of the increased risk of ESRD
among Blacks might be due to earlier initiation of dialysis,
serum creatinine and eGFR before dialysis were compared in
Blacks and non-Blacks. The last eGFR from 1 to 60 days
before renal replacement therapy was 13.4 ml/min per
1.73 m2 (s.d. 13.3) in Blacks and 14.6 ml/min per 1.73 m2
(s.d. 15.7) in non-Blacks. In addition, adding 3 months to the
time-to-ESRD in Blacks does not appreciably reduce the
higher risk observed in Blacks. This analysis suggests that the
racial difference in ESRD incidence was not due to an earlier
initiation of dialysis in Blacks. Finally, the Modification of
Diet in Renal Disease Study formula may not apply well to
some populations outside of the development and validation
samples;21,22 a large proportion of study subjects are elderly
or of non-White race/ethnicity, which may affect the accuracy
of GFR estimation.
This study is limited by missing race data in 47% of adult
health plan members with at least one serum creatinine test.
By supplementing available race data with geocoding, we
were able to assign Black or non-Black race to 96% of those
with a serum creatinine test, but at the cost of increased
misclassification. We compared the risk of ESRD and death
before ESRD with and without race imputation and found
that the HR was reduced about 8% in the subset of subjects
with known race (that is, not imputed). Owing to California
hospitalization reporting requirements, race data are often
obtained due to acute illness. Among subjects whose race was
known, 44 and 48% of non-Blacks and Blacks, respectively,
were hospitalized. Imputation captured a large proportion of
members who had little need for hospitalization: 7 and 1% of
non-Blacks and Blacks, respectively. In our judgment, the
overall bias in risk estimates is likely to be reduced by
including members who use less acute illness services,
considering the larger fraction of all members captured and
the high accuracy of our imputation method. Finally, the use
of geocoding could introduce bias if residents of predomi-
nately Black census block groups are of different socio-
economic status than residents of predominately non-Black
census block groups.
eGFR 60
eGFR 45
eGFR 30
eGFR 15
0
1
2
3
4
5
20 30 40 50 60 70 80 90
ESRD
eGFR 60
eGFR 45
eGFR 30
eGFR 15
0
1
2
3
4
5
20 30 40 50 60 70 80 90
Death before ESRD
H
R
Age at entry eGFR (years)
Figure 3 |Risk of ESRD (left) and risk of death before ESRD (right) in Blacks vs non-Blacks by study entry age and eGFR (ml/min per
1.73m2). On the basis of the competing-risk regression models with interaction terms, as shown in Table 4. Solid lines: entry eGFR 60ml/
min per 1.73m2. Long dashed lines: entry eGFR 45ml/min per 1.73m2. Dashed lines: entry eGFR 30ml/min per 1.73m2. Dotted lines: entry
eGFR 15ml/min per 1.73m2. eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.
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This study aimed to identify CKD outcomes associated
with race, sex, age, and kidney function at any given point of
time. We intentionally chose not to adjust for factors that
may be dependent on race/ethnicity. We did not attempt to
define CKD by signs of kidney damage,23 such as albumi-
nuria, which may vary between racial/ethnic groups. We did
not examine the causes of CKD (for example, diabetes,
hypertension, glomerulonephritis, and human immunodefi-
ciency virus nephropathy) or determine if death was related
to CKD. These causes may vary by race/ethnicity,1 and thus
so may risk estimates specific to any given cause.
This study included subjects from a large, integrated
health-care system and therefore may not be representative of
members of other health plans, delivery systems, and the
population at large. Income was higher in our population
than that suggested by national data, although the health plan
membership is representative of all but the highest income
Californians: based on US Census median household income,
8.9% of members and 9.2% of Californians were in the lowest
income quintile. Approximately 35–40% of health plan
members were of Hispanic ethnicity, which is similar to the
population of Southern California. In the United States
during this same time period, the population was about 13%
Hispanic (http://www.census.gov). Hispanics are at 1.47
times the risk of ESRD than non-Hispanics.1 On account
of the large proportion of Hispanic subjects, the incidence of
ESRD may be somewhat greater, and the difference between
Blacks and non-Blacks somewhat smaller, than it would be if
subjects were drawn from other US regions.
This study provides one reference point from which to
understand better the racial disparities in ESRD incidence in
the United States. In this integrated health system, Blacks had
1.8 times the risk of ESRD as non-Blacks, which is not
dissimilar to the national estimate of 2.6 times the risk.
Blacks were older at the onset of ESRD in the health plan
than nationally (62.4 years compared with 58.2 years).1 Non-
Blacks also were older at the start of ESRD in the health plan
than nationally, thus helping preserve the disparity. Member-
ship in an integrated health plan does not necessarily ensure
equivalent care; however, Gao et al.24 showed equivalent care
for moderate and severely decreased kidney function in the
Department of Defense, another integrated health system.
Moreover, different heath disparities may be more or less
amenable to uniform health care. Karter et al.25 reported
lower rates of diabetic complications in minority patients
within Kaiser Permanente Northern California for all
conditions except ESRD. Clearly, the importance of access
to equitable health care cannot be judged by the disparities
observed within any given health-care system. The federal
government provides Medicare insurance to all those aged 65
years and older; however, during the time period of this
study, about 16% of persons in the United States under age of
65 years had no health insurance. Compared with Blacks, the
percent without insurance was about 5% lower among
Whites, the same among Asians, and about 15% higher
among American Indians and Hispanics.26 To understand the
full impact of health-care coverage, it is important to
compare CKD outcomes across health systems and in the
uninsured.
In summary, this study provides evidence that despite
equivalent health insurance benefits provided within the
same integrated health-care system, the risk of ESRD was
substantially greater in Blacks than in other racial groups
combined. The risk of death before ESRD was also greater in
Blacks, except in the elderly with severely decreased kidney
function. These data reinforce the need to elucidate racial
disparities in CKD-related death and kidney function loss
from the earliest stages of kidney dysfunction. Understanding
better when risks increase and racial disparities emerge will
help lead to improved CKD outcomes, regardless of race.
MATERIALS AND METHODS
Study subjects were members of Kaiser Permanente Southern
California (hereafter referred to as the health plan), an integrated
health system that provides comprehensive care to over 3 million
active members at 11 medical centers and hundreds of satellite
clinics and service sites throughout Southern California. All
members have very similar coverage benefits and co-payments for
health-care services, including office visits, tests, and medications.
Subjects were identified from electronic health and administrative
records spanning 1 January 1998 to 31 December 2006. Vital statistics
data were obtained from California State death certificates and the
Social Security Death Index. Analyses were conducted by the research
team using SAS 9.1 (SAS Institute, Cary, NC, USA), Stata 10.1
(StataCorp, College Station, TX, USA) and the R programming
language software (http://cran.r-project.org/) developed for competing
risk regression.27 The study protocol was reviewed and approved by the
Institutional Review Board of Kaiser Permanente Southern California.
The source population was members greater than 17 years of age
with more than 1 month of enrollment in the health plan
(n¼ 5,004,022). The flow chart in Figure 1 describes the assembly
of the study cohort. Subjects were required to have at least one
outpatient serum creatinine for estimating GFR. Only outpatient
serum creatinine tests were used in order to avoid tests obtained
during acute renal failure.2,28 Fifty-one percent of these members
had an outpatient serum creatinine test at some time during the
study period (n¼ 2,542,842).
Race data were available from health plan files for 53% of
members with at least one outpatient serum creatinine test. US
Census blocks were used to impute Black vs non-Black race (that is,
geocoding) in those for whom these data were not available. Block
group cut-points were selected for a 75% or greater probability of
being either Black or non-Black based on membership home address
and known race data.29 After geocoding imputation, race data were
96% complete among members with at least one outpatient serum
creatinine test. An independent data source providing self-reported
race was used to validate study race assignment. The validation data
were from the California Men’s Health Study, a cohort established in
2002–2003 consisting of men aged 45–69 years who were members of
Northern or Southern California Kaiser Permanente.30 Of the 35,957
subjects in our study who were part of the California Men’s Health
Study cohort, the positive and negative predictive values of Black
and non-Black race assignment were 96 and 98%, respectively.
Kidney function was assessed by the abbreviated Modification of
Diet in Renal Disease Study equation, which calculates eGFR based on
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serum creatinine concentration, age, sex, and Black vs non-Black
race.21,31,32 The need for serum creatinine assay calibration was
assessed by comparing the assays at 45 different health plan lab sites
with the reference lab for the Modification of Diet in Renal Disease
Study formula, the Cleveland Clinic.33 Four serum creatinine-pooled
specimens of 0.9, 1.4, 2.9, and 3.5 mg/100 ml were distributed through
usual processes for quality control. The specimens with ±15%34 of
Cleveland Clinic results were 93, 98, 100, and 100%, respectively, and
test result means were identical to the Cleveland Clinic results, so no
attempt was made to recalibrate assays.
Subjects were passively followed through electronic health
records until an end point, which included death before ESRD
and ESRD, or were censored due to disenrollment at the end of the
observation period. Disenrollment was defined by the date after
which there was a lapse in membership for more than 1 month,
regardless of future re-enrollment. The date of initiation of
hemodialysis, peritoneal dialysis, or renal transplantation before
dialysis was used to determine the onset of ESRD. All members
undergoing temporary or chronic dialysis are tracked by the Kaiser
Permanente Southern California Renal Program. Data are entered
into a database when a required referral for dialysis is received.
Internal dialysis unit records and claims from outside facilities are
reconciled quarterly with the dialysis database. Subjects on
temporary dialysis were not considered to have reached an end
point. Dialysis within 1 day of death was considered a death.
Under conditions of competing risks, Kaplan–Meier estimates
and Cox regression models can produce misleading results, so
corresponding competing risk methods were used.35–37 Cumulative
incidence curves were used to characterize the competing risks of
ESRD and death before ESRD. Time to event was measured from the
date of eGFR to the first end point. If a member had multiple serum
creatinine tests, one test was randomly chosen as the entry eGFR.
Separate curves were prepared for ESRD, death before ESRD, and
the combined outcomes. Black and non-Black race groups were
compared within the following entry eGFR strata: 15 to o30, 30 to
o45, and 45 too60 ml/min per 1.73 m2. Differences in curves were
tested using the K-sample test developed by Gray,35 and the log-rank
test. The ratio of death to ESRD (death/ESRD) in Blacks and non-
Blacks was determined for each eGFR strata. To compare death/
ESRD in Blacks and non-Blacks with adjustment for age and sex
differences, cumulative incidence rates were directly standardized to
the year 2000 US population. The method of Fine and Gray27 was
used for regression modeling of the effect of race, with adjustment
for age, sex, and entry eGFR. With this method, the risk of each
outcome in Blacks vs non-Blacks during the entire observation
period was determined. Non-linear associations for age and eGFR
were tested. The effect of interactions between covariates on the HR
for ESRD and death before ESRD was examined. A subset analysis
was performed using only subjects whose race was known from
health plan databases (that is, race was not imputed).
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